Copper Cu-64-DOTA-alendronate
Phase 1Small molecule
Copper Cu-64-DOTA-alendronate is one of 28 small molecule programs targeting Calcification. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Calcification
#DrugCompanyPhaseTrials
1Rocaltrol
Alnylam PharmaceuticalsApproved
Eliquis
Bristol-Myers SquibbApproved
Zemplar
AbbVieApproved
Xarelto
WWim Janssens
Approved
Coumadin
AAbbott
Approved
Fosamax
OOrganon and Co
Approved
Circadin
NNeurim Pharmaceuticals Ltd.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Farxiga
AstraZenecaPhase 3
Aldactone
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Calcification1 trial
64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy
Completed·—·Phase 1·NCT03542695·1 enrolled
Locally-advanced Rectal Cancer1 trial
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
Recruiting·—·Phase 1·NCT05245786·15 enrolled
Metastatic Solid Tumors1 trial
64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation
Withdrawn·—·Phase 1·NCT05728372
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCity of Hope Medical Center